Skip to main content

Advertisement

SpringerLink
Log in

The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran’s Affairs patients receiving tumor necrosis factor alpha antagonists

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

The objective of this study was to evaluate the incidence of new onset or worsening congestive heart failure in Veteran’s Affairs (VA) patients who have received infliximab, etanercept, or adalimumab, and to compare mortality rates in these patients to control populations. We enrolled three groups of patients for this retrospective study: TNF-α group (n = 103), a rheumatoid arthritis (RA) control group (n = 100), and a control group without RA (n = 100). All patients at our VA facility who had received at least one dose of the TNF-α antagonists were included in the TNF-α group. Admissions for CHF did not differ between the three groups: TNF-α 7 (6.7%), RA control 8 (8%), non-RA control 7 (7%); P = 0.940. Mortality rates were not significantly different: TNF-α 4 (3.8%), RA control 7 (7%), non-RA control 11 (11%); P = 0.147. Our study showed no difference between the three groups in either CHF exacerbation or mortality.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL (1996) Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol 27:1201–1206

    Article  PubMed  CAS  Google Scholar 

  2. Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, Niebauer J, Hooper J, Volk HD, Coats AJ, Anker SD (2000) Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 102:3060–3067

    PubMed  CAS  Google Scholar 

  3. Deswal A, Peterson NJ, Feldman AM, Young JB, White BG, Mann DL (2001) Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the vesnarinone trial (VEST). Circulation 103:2055–2059

    PubMed  CAS  Google Scholar 

  4. Deswal A, Bozkurt B, Seta Y, Parilti-Eiswirth S, Hayes FA, Blosch C, Mann DL (1999) Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation 99:3224–3226

    PubMed  CAS  Google Scholar 

  5. Bozkurt B, Torre-Amione G, Warren MS, Whitmore J, Soran OZ, Feldman AM, Mann DL (2001) Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 103:1044–1047

    PubMed  CAS  Google Scholar 

  6. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT (2003) Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor alpha in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation 107:3133–3140

    Article  PubMed  CAS  Google Scholar 

  7. Mann DL, McMurray JV, Packer M, Swedberg K, Borer JS, Colucci WS, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, van Veldhuissen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, Fleming T (2004) Targeted anticytokine therapy in patients with chronic heart failure: Results of the randomized etanercept worldwide evaluation (RENEWAL). Circulation 109:r76–r84

    Article  Google Scholar 

  8. Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM (2003) Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 138:807–811

    PubMed  Google Scholar 

  9. de’Clari F, Salani I, Safwan E, Giannacco A (2002) Sudden death in a patient without heart failure after a single infusion of 200 mg infliximab: does TNF alpha have protective effects on the failing heart or does infliximab have direct harmful cardiovascular effects? Circulation 105:e183

    Article  Google Scholar 

  10. Khan AH, Spodick DH (1972) Rheumatoid heart disease. Semin Arthritis Rheum 1:327–337

    Article  PubMed  CAS  Google Scholar 

  11. Wolfe F, Michaud K (2004) Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 116:305–311

    Article  PubMed  Google Scholar 

  12. Hegewisch S, Weh HJ, Hossfeld DK (1990) TNF induced cardiomyopathy. Lancet 2:294–295

    Article  Google Scholar 

  13. Mann DL, Young JB (1994) Basic mechanisms in congestive heart failure: recognizing the role of proinflammatory cytokines. Chest 105:897–904

    PubMed  CAS  Google Scholar 

  14. Kelly RA, Smith TW (1997) Cytokines and cardiac contractile function. Circulation 95:778–781

    PubMed  CAS  Google Scholar 

  15. Seta Y, Shan K, Bozkurt B, Oral H, Mann DL (1996) Basic mechanisms in heart failure: the cytokine hypothesis. Card Fail 2:243–249

    Article  CAS  Google Scholar 

  16. Aikawa R, Nitta-Komatsubara Y, Kudoh S, Takano H, Nagai T, Yazaki Y, Nagai R, Komuro I (2002) Reactive oxygen species induce cardiomyocyte apoptosis partly through TNF alpha. Cytokine 18:179–183

    Article  PubMed  CAS  Google Scholar 

  17. Bradham WS, Bozkurt B, Gunasinghe H, Mann D, Spinale FG (2002) Tumor necrosis factor alpha and myocardial remodeling in progression of heart failure: a current perspective. Cardiovasc Res 53:822–830

    Article  PubMed  CAS  Google Scholar 

  18. Ferrari R, Bachetti T, Confortini R, Opasich C, Febo O, Corti A, Cassani G, Visioli O (1995) Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 92:1479–1486

    PubMed  CAS  Google Scholar 

  19. Sack MN, Smith RM, Opie LH (2000) Tumor necrosis factor in myocardial hypertrophy and ischaemia: an anti-apoptotic perspective. Cardiovasc Res 45:68–695

    Article  Google Scholar 

  20. Hofbauer KH, Schoof E, Kurtz A, Sander P (2002) Inflammatory cytokines stimulate adrenomedullin expression through nitric oxide dependent and independent pathways. Hypertension 39:161–167

    Article  PubMed  CAS  Google Scholar 

  21. Kurrelmeyer KM, Michael LH, Baumgarten G, Taffett GE, Peschon JJ, Sivasubramanian N, Entman ML, Mann DL (2000) Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc Natl Acad Sci USA 97:5456–5461

    Article  PubMed  CAS  Google Scholar 

  22. Sugamori T, Ishibashi Y, Shimada T, Takahashi N, Sakane T, Ohata S, Kunizawa Y, Inoue S, Nakamura K, Ohta Y, Shimizu H, Katoh H, Oyake N, Murakami Y, Hashimoto M (2002) Increased nitric oxide in proportion to the severity of heart failure in patients with dilated cadiomyopathy: close correlation of tumor necrosis factor with systemic and local production of nitric oxide. Circ J 266:627–632

    Article  Google Scholar 

  23. Aukrust P, Ueland T, Lien E, Bendtzen K, Muller F, Andreassen AK, Nordoy I, Aass H, Espevik T, Simonsen S, Froland SS, Gullestad L (1999) Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 83:376–382

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Pharmacy and Rheumatology, Veterans Affairs North Texas Health Care System (VANTHCS), Dallas, TX, USA

    Jennifer Cole, Anthony Busti & Salahuddin Kazi

  2. Palmetto Health Richland, University of South Carolina College of Pharmacy, 5 Medical Park Drive, Columbia, SC, 29203, USA

    Jennifer Cole

  3. Texas Tech University Health Sciences Center School of Pharmacy, Dallas/Ft. Worth Regional Campus, 4500 South Lancaster Rd., Bld 7, Dallas, TX, 75216, USA

    Anthony Busti

  4. Internal Medicine University of Texas Southwestern Medical Center, 4500 South Lancaster Rd., Suite 111, Dallas, TX, 75216, USA

    Salahuddin Kazi

Authors
  1. Jennifer Cole
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anthony Busti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Salahuddin Kazi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jennifer Cole.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cole, J., Busti, A. & Kazi, S. The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran’s Affairs patients receiving tumor necrosis factor alpha antagonists. Rheumatol Int 27, 369–373 (2007). https://doi.org/10.1007/s00296-006-0215-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-006-0215-3

Keywords

Search

Navigation